Fusion Pharmaceuticals, part of the AstraZeneca Group, is redefining precision oncology with next‑generation radioconjugates that deliver powerful alpha‑emitting payloads directly to tumors. Our pipeline spans multiple first‑in‑class programs—backed by a GMP‑compliant, state‑of‑the‑art radiopharmaceutical facility in Hamilton, we’re turning cutting‑edge science into real‑world impact for patients. Join us at the forefront of radiopharma innovation and be part of turning breakthrough science into meaningful outcomes for patients—come build what’s next with us! Note: This role is 5 days per week onsite. The Role As an Associate Director, RC Discovery – Immunohistochemistry (IHC), this role is for a recognized expert to spearhead the advancement of innovative IHC methodologies specifically for non-clinical radioconjugate discovery projects in oncology within AstraZeneca. The successful candidate will provide critical technical expertise in IHC, leading projects to evaluate and interpret complex data, and directly influence crucial go/no-go decisions for new compounds. A key focus will be driving the integration and implementation of cutting-edge IHC technologies, multiplexing strategies, and digital pathology solutions to enhance target validation, pharmacodynamics, and biomarker discovery. This new role within RC Discovery Biology involves building and leading a small team.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Manager